6 news items
Revolution Medicines to Participate in Goldman Sachs 45th Annual Global Healthcare Conference
RVMD
5 Jun 24
strategies. The company's RAS(ON) inhibitors RMC-6236, a RAS(ON) multi-selective inhibitor, RMC-6291, a RAS(ON) G12C-selective inhibitor, and RMC-9805
Revolution Medicines Reports First Quarter 2024 Financial Results and Update on Corporate Progress
RVMD
8 May 24
oncogenic variants of RAS proteins, and RAS companion inhibitors for use in combination treatment strategies. The company's RAS(ON) inhibitors RMC
Revolution Medicines to Report Financial Results for First Quarter 2024 After Market Close on May 8, 2024
RVMD
1 May 24
treatment strategies. The company's RAS(ON) inhibitors RMC-6236, a RAS(ON) multi-selective inhibitor, RMC-6291, a RAS(ON) G12C-selective inhibitor
Revolution Medicines Announces Publication on the Discovery of and Translational Research for RMC-6236, an Investigational RAS(ON) Multi-Selective Tri-Complex Inhibitor Designed to Block Full Spectrum of Oncogenic RAS(ON) Proteins
RVMD
9 Apr 24
, and RAS companion inhibitors for use in combination treatment strategies. The company's RAS(ON) inhibitors RMC-6236, a RAS(ON) multi-selective inhibitor
Revolution Medicines Announces Publications on the Discovery and Preclinical Profile of Representative of a New Class of RAS(ON) Multi-Selective Inhibitors Designed to Block Full Spectrum of Oncogenic RAS(ON) Proteins
RVMD
8 Apr 24
designed to suppress diverse oncogenic variants of RAS proteins, and RAS companion inhibitors for use in combination treatment strategies. The company's
va77tf3li60k9e3tgrce1mnq62frph6 kmp26
RVMD
4 Apr 24
strategies. The company's RAS(ON) inhibitors RMC-6236, a RAS(ON) multi-selective inhibitor, RMC-6291, a RAS(ON) G12C-selective inhibitor, and RMC-9805
- Prev
- 1
- Next